Source comparison
BPC-157 Site Rotation vs Other Peptides: Comparison
BPC-157 4–6 hours Daily or twice daily High. Daily rotation mandatory for protocols >14 days Moderate. Lipohypertrophy develops after 8–10 same-site injections Requires disciplined spatial tracking due to short half-life and frequent dosing; abdominal rotation
This comparison does not assign a generated winner or score.
- BPC-157
- 4–6 hours
- Daily or twice daily
- High. Daily rotation mandatory for protocols >14 days
- Moderate. Lipohypertrophy develops after 8–10 same-site injections
- Requires disciplined spatial tracking due to short half-life and frequent dosing; abdominal rotation field sufficient for most protocols
- Semaglutide (GLP-1)
- ~7 days
- Weekly
- Moderate. Rotate weekly within same region
- High. GI peptides more prone to site reactions
- Weekly frequency allows 4-week rotation before returning to first site; longer recovery windows reduce fibrosis risk
- TB-500 (Thymosin Beta-4)
- 2–3 hours
- Twice daily
- High. Same as BPC-157
- Moderate. Similar tissue response to BPC-157
- Short half-life demands twice-daily dosing; rotation discipline identical to BPC-157 but requires 24 distinct sites for 28-day protocols
- CJC-1295 / Ipamorelin
- CJC: ~8 days; Ipamorelin: ~2 hours
- Daily to 3× weekly depending on protocol
- Low to moderate. Depends on dosing schedule
- Low. Growth hormone secretagogues less reactive
- Ipamorelin's short half-life requires daily rotation if dosed daily; CJC allows more flexibility due to extended half-life
- The comparison underscores a critical point: BPC-157's short 4–6 hour half-life necessitates frequent dosing, which in turn demands rigorous site rotation. Weekly peptides like semaglutide give you 28 days to cycle through four abdominal quadrants before revisiting the first site—BPC-157 protocols give you 10–14 days maximum per site before tissue changes become measurable.